145,352 Shares in Lantheus Holdings, Inc. $LNTH Purchased by Galvin Gaustad & Stein LLC

Key Points

• Galvin Gaustad & Stein LLC has acquired 145,352 shares of Lantheus Holdings, Inc. for approximately $11.9 million, representing about 0.21% of the company's total shares.
• Insider Rajiv A. Patel sold 3,365,000 shares at $56.15 each, decreasing his ownership by 49.18%, while insiders in total have sold 6,812,000 shares valued at over $382 million in the past three months.
• Lantheus Holdings' recent trading performance includes a current stock price of $52.39, with analysts giving a consensus target price of $74.50 for the stock.

Galvin Gaustad & Stein LLC acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 145,352 shares of the medical equipment provider's stock, valued at approximately $11,899,000. Galvin Gaustad & Stein LLC owned about 0.21% of Lantheus at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in LNTH. State of Michigan Retirement System increased its position in shares of Lantheus by 0.6% during the first quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider's stock worth $1,620,000 after acquiring an additional 100 shares during the period. Signaturefd LLC increased its position in shares of Lantheus by 36.5% during the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 116 shares during the period. Intrust Bank NA grew its stake in shares of Lantheus by 2.9% during the first quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider's stock worth $431,000 after purchasing an additional 125 shares in the last quarter. Focus Financial Network Inc. grew its stake in shares of Lantheus by 4.0% during the second quarter. Focus Financial Network Inc. now owns 3,576 shares of the medical equipment provider's stock worth $293,000 after purchasing an additional 136 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in shares of Lantheus by 2.1% during the first quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider's stock worth $653,000 after purchasing an additional 139 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider directly owned 3,477,227 shares of the company's stock, valued at $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares of the company's stock, valued at $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,812,000 shares of company stock valued at $382,427,380 over the last three months. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $52.39 on Friday. The company has a 50-day simple moving average of $54.85 and a 200-day simple moving average of $75.05. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $118.21. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. The stock has a market capitalization of $3.56 billion, a price-to-earnings ratio of 13.93 and a beta of 0.09.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The business had revenue of $92.51 million during the quarter. On average, analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Truist Financial set a $63.00 target price on shares of Lantheus and gave the stock a "hold" rating in a research note on Monday, August 11th. TD Cowen lowered their target price on shares of Lantheus from $95.00 to $80.00 and set a "buy" rating for the company in a research note on Monday, September 15th. The Goldman Sachs Group set a $77.00 target price on shares of Lantheus and gave the stock a "neutral" rating in a research note on Wednesday. Mizuho decreased their price objective on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th. Finally, B. Riley decreased their price objective on shares of Lantheus from $109.00 to $84.00 and set a "buy" rating for the company in a research note on Tuesday, September 16th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $74.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.